Please login to the form below

Not currently logged in
Email:
Password:

CureVac

This page shows the latest CureVac news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

Immunotherapeutics and earlier alliances with Siamab, AbeXXa Biologics, CureVac and Philogen.

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    preclinical). 225. CureVac/ Sanofi Pasteur. Exercise of option,  licence. RNActive vaccine technology vs undisclosed pathogens (preclinical).

  • Pharma deals during July 2014 Pharma deals during July 2014

    Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... It will pay CureVac an

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... He brings 17 years of experience as the founder

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    Pierre Kemula joins the mRNA company’s management board. Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer. ... Kemula will have responsibility for managing CureVac's financial and capital markets

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Launch Excellence 2020
In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch...
OPEN Health reflections on the World Orphan Drug Congress in Barcelona
Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...
R&D protocol amendments
Rethinking trials: the pros and cons of protocol amendments
Protocol amendments occur often and can be beneficial, but the steps involved can be complex...

Infographics